• Urokinase Deal Announced

    Microbix and Zydus Cadila have announced that they have signed a Letter of Intent to market the Thrombolytic drug, Urokinase, in the North American markets.

    read more

  • Lumisort™

    Microbix’ LumiSort™ semen sexing technology is the result of research focused on the question of delivering high quality sexed semen to the livestock industry.

    read more

  • Virology

    Microbix has commercialized over 60 products derived from infectious pathogens cultured and processed in our Canadian laboratories.

    read more

  • Investor Portal

    Microbix holds a valuable portfolio of intellectual property in virology, large market biotherapeutic drugs, vaccine technologies, and animal reproduction technologies.

    read more

  • VIRUSMAX™

    VIRUSMAX™ technology is a process for recovery of more virus from influenza virus-infected chick embryos (eggs) to enhance influenza vaccine production.

    read more

Welcome to Microbix, manufacturer of trusted solutions for the infectious disease industry for over 25 years.